Clinical heterogeneity of SAPHO syndrome: challenging diagnose and treatment

被引:0
|
作者
Francesco Cianci
Angelo Zoli
Elisa Gremese
Gianfranco Ferraccioli
机构
[1] Istituto di Reumatologia e Scienze Affini,
[2] Università Cattolica del Sacro Cuore,undefined
[3] Institute of Rheumatology,undefined
[4] School of Medicine,undefined
[5] Catholic University of the Sacred Heart,undefined
来源
Clinical Rheumatology | 2017年 / 36卷
关键词
Biologic drugs; Hyperostosis; Osteitis; SAPHO; Skin; Treatment;
D O I
暂无
中图分类号
学科分类号
摘要
Synovitis, acne, pustulosis, hyperostosis and osteitis (SAPHO) syndrome is a rare disease which is often misdiagnosed and under-recognized, because of its peculiar and heterogeneous clinical presentation. Its main features consist of cutaneous and osteoarticular manifestations, the latter affecting more often the anterior chest wall and having typical radiologic findings. There are no validated diagnostic criteria for SAPHO and no guidelines for treatment, due mainly to its rarity; as a consequence, therapy is empirical and aimed to control pain and modifying inflammatory process. To date, the use of anti-TNF agents has been proved to be a valid alternative for patients unresponsive to conventional treatments, such as NSAIDs, corticosteroids, DMARDs and biphosphonates. The clinical heterogeneity of the disease, possibly due to differences in pathogenic mechanism of different manifestations, is challenging for both diagnosis and treatment, which should aim to control both skin and bone involvement in different clinical subsets. Here, we summarize the current status of knowledge about the SAPHO syndrome and present two cases of patients with very different disease manifestations, suggesting the need for personalized treatment.
引用
收藏
页码:2151 / 2158
页数:7
相关论文
共 50 条
  • [1] Clinical heterogeneity of SAPHO syndrome: challenging diagnose and treatment
    Cianci, Francesco
    Zoli, Angelo
    Gremese, Elisa
    Ferraccioli, Gianfranco
    CLINICAL RHEUMATOLOGY, 2017, 36 (09) : 2151 - 2158
  • [2] Clinical heterogeneity of SAPHO syndrome: Challenge of diagnosis
    Li, Chen
    Cao, Yihan
    Zhang, Wen
    MODERN RHEUMATOLOGY, 2018, 28 (03) : 432 - 434
  • [3] Inflammatory Bowel Disease and Concomitant SAPHO Syndrome: A Challenging Treatment
    GarzaOvalle, Oscar
    Hughston, Adam
    Kowalewski, Catherine
    Kundrotas, Leon
    AMERICAN JOURNAL OF GASTROENTEROLOGY, 2016, 111 : S833 - S833
  • [4] SAPHO Syndrome: Current Developments and Approaches to Clinical Treatment
    Firinu, Davide
    Garcia-Larsen, Vanessa
    Manconi, Paolo Emilio
    Del Giacco, Stefano R.
    CURRENT RHEUMATOLOGY REPORTS, 2016, 18 (06)
  • [5] SAPHO syndrome: current clinical, diagnostic and treatment approaches
    Yildirim, Tuba Demirci
    Sari, Ismail
    RHEUMATOLOGY INTERNATIONAL, 2024, 44 (11) : 2301 - 2313
  • [6] SAPHO Syndrome: Current Developments and Approaches to Clinical Treatment
    Davide Firinu
    Vanessa Garcia-Larsen
    Paolo Emilio Manconi
    Stefano R. Del Giacco
    Current Rheumatology Reports, 2016, 18
  • [7] Infliximab in the treatment of SAPHO syndrome:: Clinical experience and MRI response
    Widmer, M
    Weishaupt, D
    Brühlmann, P
    Michel, BA
    Forster, A
    ANNALS OF THE RHEUMATIC DISEASES, 2003, 62 : 250 - 251
  • [8] Is apremilast a treatment for SAPHO syndrome?
    Zhang, Ju
    Li, Yixuan
    Wang, Jing
    Jiang, Huan
    Qi, Jiaping
    Li, Chen
    Ying, Zhenhua
    JOURNAL OF DERMATOLOGICAL TREATMENT, 2024, 35 (01)
  • [9] Etanercept in the treatment of SAPHO syndrome
    Saez-Martin, Luis-Carlos
    Gomez-Castro, Susana
    Roman-Curto, Concepcion
    Palacios-Alvarez, Irene
    Fernandez-Lopez, Emilia
    INTERNATIONAL JOURNAL OF DERMATOLOGY, 2015, 54 (06) : E206 - E208
  • [10] Pamidronate treatment in SAPHO syndrome
    Guignard, S
    Job-Deslandre, C
    Sayag-Boukris, V
    Kahan, A
    JOINT BONE SPINE, 2002, 69 (04) : 392 - 396